Global Life Sciences Update
Switzerland to Become First World Health Organization BioHub
September 28, 2021
Spiez, a quaint small town close to the Bernese Alps in Switzerland, will host the first World Health Organization BioHub facility. The objective of this initiative is the safe receipt, storage, and distribution of pathogens to laboratories worldwide to make the fight against them more efficient.
On May 24, 2021, in his speech at the 74th World Health Assembly in Geneva, Swiss Health Minister Alain Berset called for “close international collaboration to ensure the timely sharing of epidemiological and clinical data as well as biological materials.”
One step in that direction was taken on the same day, when Berset and WHO Director-General Tedros Adhanom Ghebreyesus signed a memorandum of understanding (MoU) between the WHO and Switzerland by which the WHO took Switzerland up on its offer to provide space and knowledge for a global pathogen exchange. According to the MoU, Switzerland will make available its Biocontainment Laboratory in Spiez as WHO’s first BioHub.
Currently, most pathogen sharing is done bilaterally between countries and on an ad hoc basis, which can be slow and can leave some countries without access to the benefits and tools. The BioHub is set up to change this and to allow WHO member states to share biological materials with and via the facility, which will serve as a center for the safe receipt, sequencing, storage, and preparation of pathogens for distribution to other laboratories. The objective is to inform risk assessments and sustain global preparedness against pathogens, like the SARS-CoV-2 virus, which may cause an epidemic or even a pandemic.
The BioHub facility is part of WHO’s broader BioHub system for the use of biological materials, which is not limited to state laboratories but also open to other qualified entities such as manufacturers.
One step in that direction was taken on the same day, when Berset and WHO Director-General Tedros Adhanom Ghebreyesus signed a memorandum of understanding (MoU) between the WHO and Switzerland by which the WHO took Switzerland up on its offer to provide space and knowledge for a global pathogen exchange. According to the MoU, Switzerland will make available its Biocontainment Laboratory in Spiez as WHO’s first BioHub.
Currently, most pathogen sharing is done bilaterally between countries and on an ad hoc basis, which can be slow and can leave some countries without access to the benefits and tools. The BioHub is set up to change this and to allow WHO member states to share biological materials with and via the facility, which will serve as a center for the safe receipt, sequencing, storage, and preparation of pathogens for distribution to other laboratories. The objective is to inform risk assessments and sustain global preparedness against pathogens, like the SARS-CoV-2 virus, which may cause an epidemic or even a pandemic.
The BioHub facility is part of WHO’s broader BioHub system for the use of biological materials, which is not limited to state laboratories but also open to other qualified entities such as manufacturers.
弁護士広告—Sidley Austin LLP はグローバルな法律事務所です。当事務所の所在地および連絡先情報は、www.sidley.com/en/locations/offices に掲載されています。
Sidley は、本情報をクライアントおよび関係者の皆様へのサービスとして、教育目的のみに提供しています。本情報は、法的助言として解釈または依拠されるべきものではなく、また弁護士と依頼者の関係を生じさせるものでもありません。読者は、専門家の助言を求めることなく本情報に基づいて行動すべきではありません。Sidley および Sidley Austin とは、www.sidley.com/disclaimer に記載のとおり、Sidley Austin LLP およびその関連パートナーシップを指します。
© Sidley Austin LLP
Offices
Capabilities
Suggested News & Insights
Growth Meets Guardrails: Getting You Ready for the New Realm of Ad/PromoWednesday, May 13, 2026Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026Sidley Represents Opus Genetics in US$155 Million Financing With Oberland CapitalApril 21, 2026U.S. FDA Issues First Drug Supply Chain Security Act Warning Letter Targeting a Dispenser, Signaling Expanded Enforcement FocusApril 15, 2026Sidley Represents AIP in Its US$1.272 Billion Acquisition of Avanos MedicalApril 14, 2026Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from TakedaApril 3, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory